KIT and cancer: In terms of therapeutic strategies, it has become important to evaluate the frequency of CD117/KIT expression and mutation in malignancies since the emergence of the targets of the tyrosine kinase inhibitor imatinib mesylate (Gleevec) [9] a potential therapeutic agent which acts by specifically inhibiting tyrosine kinase receptor that is characteristic of a particular cancer cell, rather than non-specifically inhibiting and killing all rapidly dividing cells [10].